Understanding how bacteria communicate and how to disrupt that communication
Unravelling the Importance of Bacterial Signaling using Specific Interference Strategies
This study is exploring how bacteria talk to each other and is testing a new way to stop harmful bacteria from causing infections, which could lead to better treatments for patients without relying on traditional antibiotics.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10677641 on NIH RePORTER |
What this research studies
This research investigates the communication methods used by bacteria, specifically focusing on a process called quorum sensing. By using engineered enzymes that can interfere with these chemical signals, the study aims to control harmful bacteria without affecting beneficial ones. The approach is designed to prevent bacterial infections and biofilm formation, which are significant challenges in treating antibiotic-resistant infections. Patients may benefit from new treatment strategies that do not rely on traditional antibiotics, potentially reducing side effects and improving health outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from infections caused by antibiotic-resistant bacteria.
Not a fit: Patients with infections that are not caused by bacterial pathogens or those who do not have antibiotic-resistant infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments for bacterial infections that are resistant to current antibiotics.
How similar studies have performed: Other research has shown promise in using similar interference strategies to disrupt bacterial communication, indicating potential for success in this approach.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Elias, Mikael H — University of Minnesota
- Study coordinator: Elias, Mikael H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.